---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-23-000006"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T20:14:58.280353+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbbVie reports FY 2022 adjusted EPS $13.77 (+16.4% YoY); guides FY 2023 adjusted EPS $10.70-$11.10

## Summary
- FY 2022 net revenues $58.054B (+3.3% reported, +5.1% operational); Q4 net revenues $15.121B (+1.6% reported, +3.8% operational).
- GAAP diluted EPS FY $6.63 (+2.8%); adjusted diluted EPS $13.77 (+16.4%). Q4 GAAP diluted EPS $1.38 (-38.9%); adjusted $3.60 (+16.9%).
- Immunology portfolio FY net revenues $28.924B (+14.4%); Humira $21.237B, Skyrizi $5.165B, Rinvoq $2.522B.
- Hematologic oncology portfolio FY net revenues $6.577B (-9.0%); Imbruvica $4.568B, Venclexta $2.009B.
- 2023 adjusted diluted EPS guidance $10.70-$11.10 (excludes IPR&D and milestones); management cites U.S. Humira LOE as headwind.

## SEC filing metadata
- accession: 0001551152-23-000006
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000006/0001551152-23-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000006/abbv-20230209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-23-000006
- JSON: https://secwatch.observer/filing/0001551152-23-000006.json
- Plain text: https://secwatch.observer/filing/0001551152-23-000006.txt

## Key facts
- Earnings Releases
  AbbVie Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On February 9, 2023, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000006/0001551152-23-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.